https://scholars.lib.ntu.edu.tw/handle/123456789/623808
標題: | Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan | 作者: | Yang, Tsun-Yu CHII-MING LEE Wang, Shih-Rong Cheng, Yu-Yang Weng, Shao-En WAN-TSENG HSU |
公開日期: | 十二月-2022 | 卷: | 12 | 期: | 1 | 起(迄)頁: | 8186 | 來源出版物: | Scientific Reports | 摘要: | Angiotensin inhibition remains a cornerstone for pharmacologic management of heart failure (HF), despite being associated with decreased hemoglobin (Hb) levels. To investigate the effect of anemia and its treatment on patients with HF treated with sacubitril–valsartan (S/V), we conducted a retrospective study involving patients with recorded left ventricular ejection fractions (LVEFs) of < 40% between January 2017 and December 2019. We identified 677 patients, 37.7% of whom received S/V. The median follow-up period was 868 days. Anemia was associated with significantly decreased survival, increased mortality rates, and higher all-cause hospitalizations in S/V-using patients. We further analyzed 236 patients with HF who had recorded renal function, LVEF, and Hb at the initiation of S/V therapy to identify Hb patterns after S/V therapy. Of these patients, 35.6% exhibited decreasing Hb 12 months after S/V initiation, which was associated with a lower survival rate. Among the patients who were not prescribed anemia medications, Hb of ≥ 12 (vs. < 12 g/dL) was associated with a higher survival rate; this association was absent among the patients undergoing anemia treatment. These results emphasize that consistent screening and treatment for anemia should be implemented to reduce the morbidity and mortality of patients with HF receiving S/V. © 2022, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130199223&doi=10.1038%2fs41598-022-11886-2&partnerID=40&md5=25dea42efac32d4368a3d5b1c7127d35 https://scholars.lib.ntu.edu.tw/handle/123456789/623808 |
ISSN: | 20452322 | DOI: | 10.1038/s41598-022-11886-2 |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。